OUR FOCUS
Ewopharma has two core business units – Rx (prescription medicine) and consumer health. Our focus is on four key therapeutic areas:
- gastroenterology
- immunology
- neurology
- oncology
This focus is based on the specific, unmet medical need in these therapeutic areas within our region. Over the past 60 years we have accumulated in-depth knowledge and expertise, making Ewopharma an important name in these specific fields of the pharmaceutical sector. We develop and implement successful go-to-market strategies for specialty, rare/orphan, hospital and consumer health products.
GASTROENTEROLOGY
Ewopharma has an established gastroenterology portfolio built upon the cornerstone partnership with Dr. Falk Pharma, which began over 20 years ago. Dr. Falk products for inflammatory and chronic gastrointestinal disorders have been part of our portfolio ever since. We are particularly proud of the successful establishment of products such as Salofalk (mesalazine) and Ursofalk (ursodeoxycholic acid) in our markets, at a time when no generic alternatives had been available. More recent and equally important additions to the gastroenterology portfolio include BioGaia probiotic products, Biogen anti-TNF biosimilars, and Pharmacosmos’ state-of-the-art intravenous iron therapies.
IMMUNOLOGY
Our immunology products range from simple medications for coughs and colds to Ewopharma’s proprietary immune stimulator Isoprinosine®, an immunomodulatory agent indicated as an adjunctive treatment to standard antiviral or surgical treatment for viral infections, and the anti-TNF alpha biosimilar drugs Benepali (etanercept) and Flixabi (infliximab) licensed from Biogen.
NEUROLOGY
Within our neurology portfolio, we focus on degenerative central nervous system (CNS) disorders and, in particular, diseases that affect the musculoskeletal apparatus. We currently market products for multiple sclerosis (MS), Parkinson’s disease (PD), spinal muscular atrophy (SMA) and epilepsy, but are looking to expand our portfolio with further treatments in this area, as well as those for rare diseases and other niche products. One breakthrough therapy we have launched in this field is Biogen Spinraza for SMA patients.
ONCOLOGY
The partnership with Eisai forms the foundation of Ewopharma’s oncology portfolio, which includes Halaven (eribulin mesylate) for locally advanced or metastatic breast cancer, Lenvima (lenvatinib) for the treatment of certain kinds of thyroid or liver cancer as well as endometrial cancer and Kisplyx (lenvatinib) for adults with advanced renal cell carcinoma. Ewopharma has also added CStone Pharmaceuticals’ Cejemly (sugemalimab), a monoclonal antibody used for the treatment of metastatic non-small cell lung cancer, to its portfolio. To complete the current oncology pipeline, Ewopharma has secured rights to Can-Fite Biopharma’s proprietary compound namodenoson, which is being developed for certain types of liver and pancreatic cancer.